FDA-cleared AI app for point-of-care diagnosis of heart failure launched
Click Here to Manage Email Alerts
Key takeaways:
- An FDA-cleared AI app was launched for use on a handheld ultrasound device.
- The AI is designed to assist in timely, point-of-care diagnosis of heart failure.
Exo announced the launch of its FDA-cleared AI imaging applications for the diagnosis of heart failure on its handheld ultrasound device.
The AI app (Exo Iris) is designed to improve point-of-care access to timely HF diagnosis, particularly in rural and under-resourced settings, according to a press release from the company.
Trained on more than 100,000 point-of-care ultrasound images, the AI can measure left ventricle ejection fraction and stroke volume in both parasternal long axis and apical four-chamber views, the company stated in the release. The AI also features pulsed-wave Doppler capabilities assess blood velocity and support diagnosis in cardiac, abdominal and vascular applications, according to the release.
“Now I have a fast and reliable clinical tool to help easily distinguish between COPD and [congestive] HF patients for precise and timely care,” Ted Koutouzis, MD, clinical instructor in emergency medicine at Northwestern Medicine, said in the release. “What’s even more exciting is how these applications open ultrasound technology to a whole new set of [point-of-care ultrasound] users, especially those with limited experience. When clinicians can perform medical imaging efficiently, it’s a win-win for both the patients we serve and the health care systems we work within.”
Collapse
Click Here to Manage Email Alerts